There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. After-hours trades for Bristol-Myers Squibb Company (BMY) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.01, or -0.01%, to $71.00. The Bristol-Myers Squibb Company has recorded 3,002,243 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that Biking the Globe for C2C4C.
As a NYSE listed company, BMY falls under the Healthcare sector while operating within the Drug Manufacturers – General industry segment. At the end of the last regular session, the stock closed at $71.01 and fluctuated between $73.16 as its day high and $70.75 as its day low. The current market capitalization of Bristol-Myers Squibb Company is $148.75B. A total of 13.0 million shares were traded on the day, compared to an average of 9.01M shares.
Aside from predicting where a stock will go, investors also consider insider trades as an indicator of the stock’s future direction. During the recent three months, BMY has seen 8 BUY and 5 SELL insider trades, representing the acquisition of 72,825 and the disposition of 72,505 shares. Over the last 12 months, there were 86 BUYs and 57 SELLs from insiders. Insiders purchased 864,675 shares during that period but sold 878,019.
In the most recent transaction, Powell Ann sold 16,250 shares of BMY for 80.45 per share on Nov 09. After the transaction, the EVP, Chief Human Resources now owns 34,226 company shares. In a previous transaction on Nov 07, VESSEY RUPERT sold 45,910 shares at 78.88 per share. BMY shares that EVP, Research & Early Dev. owns now total 57,079.
Among the insiders who sold shares, Caforio Giovanni disposed of 25,000 shares on Sep 20 at a per-share price of $69.71. This resulted in the Board Chair and CEO holding 476,104 shares of BMY after the transaction. In another insider transaction, Caforio Giovanni sold 50,000 shares at $71.84 per share on Sep 15. Company shares held by the Board Chair and CEO now total 501,104.
Investors prefer companies that pay dividends because dividends generate immediate cash flow and indicate a positive outlook. Bristol-Myers Squibb Company pays an annual dividend of $2.28, resulting in a dividend yield of 3.21%, and it has a price to earnings (P/E) ratio of 23.15. BMY’s most recent ex-dividend date was 1/5/2023 when it declared a $0.57 quarterly dividend that was paid in cash on 2/1/2023. Previously, the company paid the dividend on 11/1/2022 with an ex-dividend date of 10/6/2022. The BMY stock dividend was $0.54 per share in cash.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. According to analysts who have offered 12-month price targets for BMY in the last 3 months, the mean price target is $81.05 with high estimates of $92.00 and low estimates of $60.00. In terms of 52-week highs and lows, BMY has a high of $81.43 and a low of $61.19.
As of this writing, BMY has an earnings estimate of $1.72 per share for the current quarter. EPS was calculated based on a consensus of 15 estimates, with a high estimate of $1.82 per share and a lower estimate of $1.58. The company reported an EPS of $1.93 in the last quarter, which was 7.80% higher than expectations of $1.79.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 21 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BMY is Sell with a score of 3.71. A total of 9 analysts rated the stock as Buy while 1 rated it as Overweight while 10 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 1 thought it should be Sold.